High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Scientific instrument company Bruker (NASDAQ:BRKR) missed Wall Street’s revenue expectations in Q2 CY2026, but sales rose 5.2% year on year to $838.5 million. The company’s full-year revenue guidance of $3.56 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $0.49 per share was 27.5% above analysts’ consensus estimates.
Bruker recently saw its shares weaken further as investors weighed an upcoming Q1 earnings report and fresh insider selling activity against current valuation metrics suggesting the stock is trading below one estimate of intrinsic value. The combination of flat year-on-year revenue expectations, past revenue guidance that exceeded forecasts despite an EPS miss, and a gap to intrinsic value estimates is sharpening focus on whether the forthcoming results can shift sentiment. With analysts...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s return was flat while the S&P 500 climbed by 5%.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.